Novel structured reporting systems for theranostic radiotracers

Rudolf A. Werner, Ralph A. Bundschuh, Lena Bundschuh, Stefano Fanti, Mehrbod S. Javadi, Takahiro Higuchi, Alexander Weich, Kenneth J. Pienta, Andreas K. Buck, Martin G. Pomper, Michael A. Gorin, Ken Herrmann, Constantin Lapa, Steven P. Rowe

Research output: Contribution to journalArticle

Abstract

Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.

Original languageEnglish
Pages (from-to)577-584
Number of pages8
JournalJournal of Nuclear Medicine
Volume60
Issue number5
DOIs
Publication statusPublished - May 1 2019
Externally publishedYes

Fingerprint

Nuclear Medicine
Somatostatin
Radiology
Multicenter Studies
Prostate
Neoplasms
Prostatic Neoplasms
Medicine
Pathology
Membranes
Theranostic Nanomedicine

Keywords

  • Ga-DOTANOC
  • Ga-DOTATATE
  • Ga-DOTATOC
  • Neuroendocrine neoplasia
  • Prostate cancer
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Werner, R. A., Bundschuh, R. A., Bundschuh, L., Fanti, S., Javadi, M. S., Higuchi, T., ... Rowe, S. P. (2019). Novel structured reporting systems for theranostic radiotracers. Journal of Nuclear Medicine, 60(5), 577-584. https://doi.org/10.2967/jnumed.118.223537

Novel structured reporting systems for theranostic radiotracers. / Werner, Rudolf A.; Bundschuh, Ralph A.; Bundschuh, Lena; Fanti, Stefano; Javadi, Mehrbod S.; Higuchi, Takahiro; Weich, Alexander; Pienta, Kenneth J.; Buck, Andreas K.; Pomper, Martin G.; Gorin, Michael A.; Herrmann, Ken; Lapa, Constantin; Rowe, Steven P.

In: Journal of Nuclear Medicine, Vol. 60, No. 5, 01.05.2019, p. 577-584.

Research output: Contribution to journalArticle

Werner, RA, Bundschuh, RA, Bundschuh, L, Fanti, S, Javadi, MS, Higuchi, T, Weich, A, Pienta, KJ, Buck, AK, Pomper, MG, Gorin, MA, Herrmann, K, Lapa, C & Rowe, SP 2019, 'Novel structured reporting systems for theranostic radiotracers', Journal of Nuclear Medicine, vol. 60, no. 5, pp. 577-584. https://doi.org/10.2967/jnumed.118.223537
Werner, Rudolf A. ; Bundschuh, Ralph A. ; Bundschuh, Lena ; Fanti, Stefano ; Javadi, Mehrbod S. ; Higuchi, Takahiro ; Weich, Alexander ; Pienta, Kenneth J. ; Buck, Andreas K. ; Pomper, Martin G. ; Gorin, Michael A. ; Herrmann, Ken ; Lapa, Constantin ; Rowe, Steven P. / Novel structured reporting systems for theranostic radiotracers. In: Journal of Nuclear Medicine. 2019 ; Vol. 60, No. 5. pp. 577-584.
@article{47f8c8567f5b4ecaac489a0e7e495f5a,
title = "Novel structured reporting systems for theranostic radiotracers",
abstract = "Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.",
keywords = "Ga-DOTANOC, Ga-DOTATATE, Ga-DOTATOC, Neuroendocrine neoplasia, Prostate cancer, Somatostatin receptor",
author = "Werner, {Rudolf A.} and Bundschuh, {Ralph A.} and Lena Bundschuh and Stefano Fanti and Javadi, {Mehrbod S.} and Takahiro Higuchi and Alexander Weich and Pienta, {Kenneth J.} and Buck, {Andreas K.} and Pomper, {Martin G.} and Gorin, {Michael A.} and Ken Herrmann and Constantin Lapa and Rowe, {Steven P.}",
year = "2019",
month = "5",
day = "1",
doi = "10.2967/jnumed.118.223537",
language = "English",
volume = "60",
pages = "577--584",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - Novel structured reporting systems for theranostic radiotracers

AU - Werner, Rudolf A.

AU - Bundschuh, Ralph A.

AU - Bundschuh, Lena

AU - Fanti, Stefano

AU - Javadi, Mehrbod S.

AU - Higuchi, Takahiro

AU - Weich, Alexander

AU - Pienta, Kenneth J.

AU - Buck, Andreas K.

AU - Pomper, Martin G.

AU - Gorin, Michael A.

AU - Herrmann, Ken

AU - Lapa, Constantin

AU - Rowe, Steven P.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.

AB - Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.

KW - Ga-DOTANOC

KW - Ga-DOTATATE

KW - Ga-DOTATOC

KW - Neuroendocrine neoplasia

KW - Prostate cancer

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=85065542102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065542102&partnerID=8YFLogxK

U2 - 10.2967/jnumed.118.223537

DO - 10.2967/jnumed.118.223537

M3 - Article

C2 - 30796171

AN - SCOPUS:85065542102

VL - 60

SP - 577

EP - 584

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -